Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02218021 · ClinicalTrials.gov registry record · Phase 1
A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users
A Phase 1 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
NCT02218021 is a Phase 1 study that has completed, run by Alkermes. The registered enrollment target is 59 participants.
The verdict
NCT02218021, a Phase 1 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the abuse potential and safety of samidorphan in healthy, non-dependent, adult, recreational opioid users.
Interventions
- DRUG Placebo
- DRUG Oxycodone
- DRUG Samidorphan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2014-08 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02218021
The ClinicalTrials.gov registry entry for NCT02218021 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02218021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02218021 about?
NCT02218021 is a clinical study titled "A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users". The purpose of this study is to evaluate the abuse potential and safety of samidorphan in healthy, non-dependent, adult, recreational opioid users.
What is the current status of trial NCT02218021?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2014-08. Estimated completion is 2014-11.
What interventions are being tested in trial NCT02218021?
The interventions under investigation include: Placebo (DRUG), Oxycodone (DRUG), Samidorphan (DRUG).
Who is sponsoring clinical trial NCT02218021?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.